Sandoz International GmbH
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sandoz International GmbH
Biocon Biologics is seeking to bolster its biosimilars business in Australia, recently integrated after being acquired from former owner Viatris, through a deal that will see Sandoz market its Ogivri and Abevmy versions of trastuzumab and bevacizumab.
Sandoz nominated a new director candidate ahead of its annual meeting and Lantheus welcomed a familiar face as the new CEO. Meanwhile, Mallinckrodt strengthened its board with four new directors and Hikma announced another appointment this year.
Sandoz reduced established conditions by 19% in one BLA; others are having similar successes in focusing change control oversight more narrowly. But there have been some pitfalls.
Sandoz is rolling out its Tyruko natalizumab biosimilar rival to Biogen’s Tysabri in Germany, heralding the product as the “first and only biosimilar for multiple sclerosis.”
- Generic Drugs
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.